Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

Julie R Lundgren, Charlotte Janus, Simon B K Jensen, Christian R Juhl, Lisa M Olsen, Rasmus M Christensen, Maria S Svane, Thomas Bandholm, Kirstine N Bojsen-Møller, Martin B Blond, Jens-Erik B Jensen, Bente M Stallknecht, Jens J Holst, Sten Madsbad, Signe S Torekov

158 Citationer (Scopus)


BACKGROUND Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous–intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, −4.1 kg (95% confidence interval [CI], −7.8 to −0.4; P=0.03); in the liraglutide group, −6.8 kg (95% CI, −10.4 to −3.1; P<0.001); and in the combination group, −9.5 kg (95% CI, −13.1 to −5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, −5.4 kg; 95% CI, −9.0 to −1.7; P=0.004) but not liraglutide (−2.7 kg; 95% CI, −6.3 to 0.8; P=0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (−1.7 percentage points; 95% CI, −3.2 to −0.2; P=0.02) and the liraglutide group (−1.9 percentage points; 95% CI, −3.3 to −0.5; P=0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone.

TidsskriftThe New England journal of medicine
Udgave nummer18
Sider (fra-til)1719-1730
Antal sider12
StatusUdgivet - 6 maj 2021


Dyk ned i forskningsemnerne om 'Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined'. Sammen danner de et unikt fingeraftryk.